Additionally, SMARCA4 mutations are recognized as a genetic factor associated with poor clinical outcomes in lung cancer, regardless of whether patients undergo immunotherapy or non-immunotherapy treatments (13). This evidence concerns the gene SMARCA4 and lung carcinoma.